White blood cell count predicts infarct size in STEMI

December 19, 2013
White blood cell count predicts infarct size in STEMI

(HealthDay)—For patients with anterior wall ST-segment elevated myocardial infarction (STEMI), elevated white blood cell count (WBCc) on presentation is associated with increased infarct size, according to a study published in the Dec. 15 issue of The American Journal of Cardiology.

Tullio Palmerini, M.D., from Policlinico S. Orsola in Bologna, Italy, and colleagues examined whether elevated WBCc correlates with increased infarct size measured with cardiac 30 days after primary . Data were from 407 participants with STEMI and proximal or mid-left anterior descending coronary artery occlusion from the Intracoronary Abciximab and Aspiration Thrombectomy in Patients With Large Anterior Myocardial Infarction trial. Participants were stratified according to WBCc tertiles.

The researchers observed an increase in infarct size (percentage of total left ventricular mass) at 30 days across tertiles of increasing WBCcs (median for tertiles I versus II versus III, 11.2 versus 17.5 versus 19.1 percent; P < 0.0001). Across tertiles of WBCc, absolute infarct mass in grams and abnormal wall motion score also increased significantly. WBCc independently predicted infarct size in multivariate analysis, together with intracoronary abciximab randomization, age, time from onset of symptoms to first device, proximal left anterior descending location, and baseline Thrombolysis In Myocardial Infarction flow of 0/1.

"In conclusion, in patients with anterior wall STEMI, an elevated admission WBCc is a powerful independent predictor of infarct size measured with cardiac magnetic resonance imaging 30 days after primary percutaneous coronary intervention," the authors write.

Two authors disclosed financial ties to the medical device industry.

Explore further: Infusion of drug into the coronary artery may help reduce size of heart damage after heart attack

More information: Abstract
Full Text (subscription or payment may be required)

Related Stories

Infusion of drug into the coronary artery may help reduce size of heart damage after heart attack

March 25, 2012
Administration of a bolus dose of the anticoagulant drug abciximab into the coronary artery involved in causing a certain type of heart attack among patients who were undergoing a percutaneous coronary intervention and also ...

Results of the CHILL-MI trial presented

October 31, 2013
A clinical trial shows that rapidly cooling patients who have suffered ST-elevation myocardial infarction (STEMI, the most serious form of a heart attack) prior to restoring blood flow is safe and feasible. The findings of ...

Study confirms that intracoronary and intravenous use of abciximab during angioplasty yield similar results

October 25, 2012
A study confirmed no differences in various measures of heart damage, according to cardiac magnetic resonance (MRI) imaging, in patients receiving the anti-clotting medication abxicimab directly into the heart (intracoronary) ...

Results of the TATORT-NSTEMI trial presented

November 1, 2013
According to a new study, aspirating blood clots does not significantly reduce microvascular obstruction or reduce the risk of death in patients with non-ST-elevation myocardial infarction (NSTEMI), when compared to standard ...

Bone marrow mononuclear stem cells show no new gains in heart function, says TIME study

November 18, 2013
New data reported by the Cardiovascular Cell Therapy Research Network (CCTRN) at the 2013 Scientific Sessions of the American Heart Association in Dallas showed that the use of bone marrow mononuclear stem cells (BMCs) did ...

Gender influences ischemic time, outcomes after STEMI

February 18, 2013
(HealthDay)—After ST-segment elevation myocardial infarction (STEMI) and primary percutaneous coronary intervention (PCI), women have longer ischemic times and are at a higher risk than men of early all-cause and cardiac ...

Recommended for you

A nanoparticle inhalant for treating heart disease

January 18, 2018
A team of researchers from Italy and Germany has developed a nanoparticle inhalant for treating people suffering from heart disease. In their paper published in the journal Science Translational Medicine, the group describes ...

Starting periods before age of 12 linked to heightened risk of heart disease and stroke

January 15, 2018
Starting periods early—before the age of 12—is linked to a heightened risk of heart disease and stroke in later life, suggests an analysis of data from the UK Biobank study, published online in the journal Heart.

'Decorated' stem cells could offer targeted heart repair

January 10, 2018
Although cardiac stem cell therapy is a promising treatment for heart attack patients, directing the cells to the site of an injury - and getting them to stay there - remains challenging. In a new pilot study using an animal ...

Two simple tests could help to pinpoint cause of stroke

January 10, 2018
Detecting the cause of the deadliest form of stroke could be improved by a simple blood test added alongside a routine brain scan, research suggests.

Exercise is good for the heart, high blood pressure is bad—researchers find out why

January 10, 2018
When the heart is put under stress during exercise, it is considered healthy. Yet stress due to high blood pressure is bad for the heart. Why? And is this always the case? Researchers of the German Centre for Cardiovascular ...

Heart-muscle patches made with human cells improve heart attack recovery

January 10, 2018
Large, human cardiac-muscle patches created in the lab have been tested, for the first time, on large animals in a heart attack model. This clinically relevant approach showed that the patches significantly improved recovery ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.